Across TCGA pan-cancer cohorts, SMTNL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated SMTNL2 data layer compared with 20 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher SMTNL2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SMTNL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and LSCC show a favorable association.

CCRCC, HNSC, and LUAD are the cancer types where SMTNL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Tertile	III,IV	0.763	0.245	.001	33	view →
HNSC	OS	Tertile	All	0.933	1.000	.017	7	view →
LUAD	DFS	Median	III,IV	0.426	0.854	.040	6	view →
LSCC	OS	Quartile	All	0.971	0.814	.019	1	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

Exploration

Same gene, other analysis: SMTNL2 tumor-vs-normal RNA expression · all SMTNL2 data types